Table 6.
Median duration of symptoms in days, according to COVID-19 severity and treatments administered during the acute phase.
| Moderate Disease | Severe Disease | ||||
|---|---|---|---|---|---|
| Treatments | n | p50 (p25–p75) * | n | p50 (p25–p75) | |
| Remdesivir | No | 472 | 262 (217, 304) | 296 | 284 (216, 336) |
| Yes | 43 | 109 (45, 143) | 36 | 187 (131, 188) | |
| Tocilizumab or Sarilumab | No | 466 | 256 (143, 303) | 193 | 292 (216, 336) |
| Yes | 49 | 252 (150, 298) | 139 | 269 (175, 325) | |
| Methylprednisolone or Prednisone | No | 395 | 256 (138, 300) | 126 | 255 (158, 312) |
| Yes | 120 | 252 (153, 308) | 206 | 294 (220, 336) | |
| Dexamethasone | No | 285 | 271 (236, 308) | 87 | 309 (239, 341) |
| Yes | 230 | 133 (63, 298) | 245 | 266 (158, 330) | |
* Data expressed as median of days and interquartile range [p50 (p25–p75)] unless otherwise specified.